The University of Virginia Cancer Center is conducting a two phase clinical research study for patients who are adults ages 18 and over, have a solid tumor cancer (not including melanoma and hepatocellular carcinoma) in Phase I and pancreatic, ovarian, or cholangiocarcinoma cancer in Phase 2, and have already tried other therapies to treat their cancer.
The purpose of Phase 1 portion this study to determine the appropriate dose and safety of an investigational drug (ZB131) in participants with solid tumor cancers (not including melanoma and hepatocellular carcinoma). In the Phase 2 portion of the study, the focus will be on how pancreatic, ovarian, or cholangiocarcinoma cancers respond to ZB131 at the recommended Phase 2 dose (as established in Phase I). The investigational drug dose safety, and effects of the experimental drug will be evaluated for this study.
Participation includes a screening period, 21-day cycles of study treatment, and a safety follow-up period via a clinic visit l to keep track of how you are doing. Study specific test(s) will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05074472
You may receive compensation and/or reimbursement for this trial to assist with travel expenses for this trial.